Genprex Inc.

Genprex Inc.https://investorshangout.com/Genprex-Inc-GNPX-92681/en-usWed, 02 Sep 2026 03:20:53 GMTCopyright InvestorsHangout.comLee Adams: Genprex Receives Safety Review Committee Approval to Advance to Highest Dose Group in Phase 1 Porhttps://investorshangout.com/post/view?id=6723775https://investorshangout.com/post/view?id=6723775Tue, 15 Oct 2024 13:52:25 GMTLee Adams: Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy athttps://investorshangout.com/post/view?id=6722969https://investorshangout.com/post/view?id=6722969Thu, 10 Oct 2024 13:37:06 GMTLee Adams: $GNPX News: Genprex Collaborators to Present Positive Preclinical Data on Reqorsa® Gene Therapy ahttps://investorshangout.com/post/view?id=6722191https://investorshangout.com/post/view?id=6722191Mon, 07 Oct 2024 13:38:44 GMTLee Adams: $GNPX News: Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® Genhttps://investorshangout.com/post/view?id=6717278https://investorshangout.com/post/view?id=6717278Mon, 09 Sep 2024 13:35:58 GMTLee Adams: $GNPX News: Genprex Announces Plans to Launch Separate Company to Focus on the Development of Genhttps://investorshangout.com/post/view?id=6716526https://investorshangout.com/post/view?id=6716526Wed, 04 Sep 2024 13:42:22 GMTLee Adams: $GNPX News: Genprex to Present and Participate at Upcoming September Investor and Industry Conferenchttps://investorshangout.com/post/view?id=6716340https://investorshangout.com/post/view?id=6716340Tue, 03 Sep 2024 14:10:05 GMTtrooperstocks: $GNPX News: Genprex to Present at the 2024 BIO International Convention PR Newswire Thu, Mahttps://investorshangout.com/post/view?id=6697288https://investorshangout.com/post/view?id=6697288Thu, 30 May 2024 13:10:09 GMTLee Adams: $GNPX News: Genprex Doses First Patient in Acclaim-3 Clinical Study of Reqorsa® Immunogene Theraphttps://investorshangout.com/post/view?id=6693488https://investorshangout.com/post/view?id=6693488Tue, 14 May 2024 14:27:39 GMTLee Adams: $GNPX News: Genprex Announces the Appointment of Jose A. Moreno Toscano as Chairman of the Board https://investorshangout.com/post/view?id=6693238https://investorshangout.com/post/view?id=6693238Mon, 13 May 2024 18:20:58 GMTNetworkNewsWire: NetworkNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Announces Positive Preclinical Data Supporting NPhttps://investorshangout.com/post/view?id=6681854https://investorshangout.com/post/view?id=6681854Tue, 02 Apr 2024 21:01:34 GMTNetworkNewsWire: NetworkNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Closes on $6.5M Registered Direct Offering https://investorshangout.com/post/view?id=6680131https://investorshangout.com/post/view?id=6680131Mon, 25 Mar 2024 20:29:05 GMTNetworkNewsWire: NetworkNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Releases Info on $6.5M Registered Direct Offeringhttps://investorshangout.com/post/view?id=6679192https://investorshangout.com/post/view?id=6679192Wed, 20 Mar 2024 21:25:50 GMTNetworkNewsWire: NetworkNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Announces $6.5M Registered Direct Offering https://investorshangout.com/post/view?id=6678964https://investorshangout.com/post/view?id=6678964Tue, 19 Mar 2024 20:51:25 GMTNetworkNewsWire: NetworkNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Announces New Research Collaborations, Expansion https://investorshangout.com/post/view?id=6669831https://investorshangout.com/post/view?id=6669831Wed, 07 Feb 2024 20:04:34 GMTNetworkNewsWire: NetworkNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Announces Participation at This Month’s BIO CEO &https://investorshangout.com/post/view?id=6669530https://investorshangout.com/post/view?id=6669530Tue, 06 Feb 2024 20:05:52 GMTNetworkNewsWire: NetworkNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Phase2a Expansion of Acclaim-1 Clinical Study Enrhttps://investorshangout.com/post/view?id=6669236https://investorshangout.com/post/view?id=6669236Mon, 05 Feb 2024 21:13:07 GMTwhytestocks: $GNPX News Article - Genprex Provides Business Update and Outlook for 2024 https://investorshangout.com/post/view?id=6660428https://investorshangout.com/post/view?id=6660428Fri, 05 Jan 2024 20:35:47 GMTNetworkNewsWire: Genprex Inc. (NASDAQ: GNPX) Granted Orphan Drug Designation in Small Cell Lung Cancer by FDA, Prehttps://investorshangout.com/post/view?id=6646521https://investorshangout.com/post/view?id=6646521Wed, 22 Nov 2023 20:50:38 GMTNetworkNewsWire: NetworkNewsBreaks – Genprex Inc. (NASDAQ: GNPX) to Present at BIO-Europe 2023 Genprex (NAShttps://investorshangout.com/post/view?id=6639807https://investorshangout.com/post/view?id=6639807Wed, 01 Nov 2023 20:23:14 GMTNetworkNewsWire: NetworkNewsBreaks – Genprex Inc. (NASDAQ: GNPX) to Unveil Encouraging Data on REQORSA(R) for Lunghttps://investorshangout.com/post/view?id=6626738https://investorshangout.com/post/view?id=6626738Wed, 04 Oct 2023 21:23:44 GMTwhytestocks: $GNPX News Article - Genprex to Present Data on the Use of REQORSA for the Treatment of Lung Cancerhttps://investorshangout.com/post/view?id=6626516https://investorshangout.com/post/view?id=6626516Wed, 04 Oct 2023 16:05:52 GMTNetworkNewsWire: Pathways to Progress: How Orphan Drug Designation Sparks Biotech Transformation NetworkNewhttps://investorshangout.com/post/view?id=6620755https://investorshangout.com/post/view?id=6620755Wed, 20 Sep 2023 20:05:25 GMTNetworkNewsWire: NetworkNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Building Protection and Powerful IP Portfolio forhttps://investorshangout.com/post/view?id=6620746https://investorshangout.com/post/view?id=6620746Wed, 20 Sep 2023 19:51:10 GMTNetworkNewsWire: NetworkNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Looks Forward to Acclaim-3 Trial on Heels of Recehttps://investorshangout.com/post/view?id=6619158https://investorshangout.com/post/view?id=6619158Fri, 15 Sep 2023 20:43:16 GMTNetworkNewsWire: NetworkNewsBreaks – Genprex Inc. (NASDAQ: GNPX) to Present at Upcoming H.C. Wainwright Conferencehttps://investorshangout.com/post/view?id=6616375https://investorshangout.com/post/view?id=6616375Thu, 07 Sep 2023 20:13:17 GMTNetworkNewsWire: Genprex Inc. (NASDAQ: GNPX) Obtains New License for Novel Diabetes Gene Therapy Pipeline -https://investorshangout.com/post/view?id=6615434https://investorshangout.com/post/view?id=6615434Tue, 05 Sep 2023 20:23:43 GMTwhytestocks: $GNPX News Article - Genprex Inc. (NASDAQ: GNPX) Obtains New License for Novel Diabetes Gene Therapyhttps://investorshangout.com/post/view?id=6615343https://investorshangout.com/post/view?id=6615343Tue, 05 Sep 2023 17:50:50 GMTNetworkNewsWire: NetworkNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Secures Patent Protection in ‘Some of the Most Imhttps://investorshangout.com/post/view?id=6614614https://investorshangout.com/post/view?id=6614614Fri, 01 Sep 2023 20:14:09 GMTNetworkNewsWire: Genprex Inc. (NASDAQ: GNPX) Celebrates Receipt of Orphan Drug Designation, Third Fast Track Desighttps://investorshangout.com/post/view?id=6613781https://investorshangout.com/post/view?id=6613781Wed, 30 Aug 2023 20:31:31 GMTNetworkNewsWire: NetworkNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Appoints Regulatory Expert as It Drives Importanthttps://investorshangout.com/post/view?id=6611127https://investorshangout.com/post/view?id=6611127Tue, 22 Aug 2023 21:15:22 GMTwhytestocks: $GNPX News Article - InvestorNewsBreaks - Genprex Inc. (NASDAQ: GNPX) Appoints Regulatory Expert as https://investorshangout.com/post/view?id=6610947https://investorshangout.com/post/view?id=6610947Tue, 22 Aug 2023 16:05:48 GMTNetworkNewsWire: NetworkNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Granted FDA Orphan Drug Designation for REQORSA(Rhttps://investorshangout.com/post/view?id=6606787https://investorshangout.com/post/view?id=6606787Thu, 10 Aug 2023 19:33:45 GMTwhytestocks: $GNPX News Article - InvestorNewsBreaks - Genprex Inc. (NASDAQ: GNPX) Granted FDA Orphan Drug Designhttps://investorshangout.com/post/view?id=6606780https://investorshangout.com/post/view?id=6606780Thu, 10 Aug 2023 19:25:46 GMTwhytestocks: $GNPX News Article - Genprex Granted FDA Orphan Drug Designation (ODD) for REQORSA Immunogene Therahttps://investorshangout.com/post/view?id=6606760https://investorshangout.com/post/view?id=6606760Thu, 10 Aug 2023 18:35:47 GMTNetworkNewsWire: NetworkNewsBreaks – Genprex Inc.’s (NASDAQ: GNPX) Third Fast Track Designation Validates REQORSA(https://investorshangout.com/post/view?id=6604762https://investorshangout.com/post/view?id=6604762Fri, 04 Aug 2023 21:28:07 GMTNetworkNewsWire: Genprex Inc. (NASDAQ: GNPX) Secures Exclusivity for REQORSA(R)-Keytruda(R) Drug Combination in Chhttps://investorshangout.com/post/view?id=6601994https://investorshangout.com/post/view?id=6601994Fri, 28 Jul 2023 20:32:06 GMTwhytestocks: $GNPX News Article - Genprex Inc. (NASDAQ: GNPX) Secures Exclusivity for REQORSA(R)-Keytruda(R) Drughttps://investorshangout.com/post/view?id=6601869https://investorshangout.com/post/view?id=6601869Fri, 28 Jul 2023 17:20:49 GMTNetworkNewsWire: NetworkNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Announces $7.5M Registered Direct Offering https://investorshangout.com/post/view?id=6598088https://investorshangout.com/post/view?id=6598088Wed, 19 Jul 2023 21:14:33 GMTNetworkNewsWire: NetworkNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Enters Exclusive License Agreement with Universithttps://investorshangout.com/post/view?id=6597616https://investorshangout.com/post/view?id=6597616Tue, 18 Jul 2023 20:42:44 GMTwhytestocks: $GNPX News Article - InvestorNewsBreaks - Genprex Inc. (NASDAQ: GNPX) Enters Exclusive License Agreehttps://investorshangout.com/post/view?id=6597458https://investorshangout.com/post/view?id=6597458Tue, 18 Jul 2023 16:25:47 GMTNetworkNewsWire: NetworkNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Positioned to Expand Its Clinical Pipeline https://investorshangout.com/post/view?id=6597093https://investorshangout.com/post/view?id=6597093Mon, 17 Jul 2023 20:22:00 GMTNetworkNewsWire: Genprex Inc. (NASDAQ: GNPX) Reports Positive Results from its Phase 1 Acclaim-1 Clinical Trial; Rhttps://investorshangout.com/post/view?id=6594637https://investorshangout.com/post/view?id=6594637Mon, 10 Jul 2023 21:01:45 GMTNetworkNewsWire: Genprex, Inc. (NASDAQ: GNPX) Receives Third Fast Track Designation for REQORSA(R), Setting Stage https://investorshangout.com/post/view?id=6593495https://investorshangout.com/post/view?id=6593495Thu, 06 Jul 2023 20:16:11 GMTNetworkNewsWire: NetworkNewsBreaks – Genprex Inc.’s (NASDAQ: GNPX) Unique Treatment Paradigm Featured in Bell2Bellhttps://investorshangout.com/post/view?id=6593492https://investorshangout.com/post/view?id=6593492Thu, 06 Jul 2023 20:10:29 GMTwhytestocks: $GNPX News Article - InvestorNewsBreaks - Genprex Inc. (NASDAQ: GNPX) Receives Fast Track Designatiohttps://investorshangout.com/post/view?id=6590811https://investorshangout.com/post/view?id=6590811Wed, 28 Jun 2023 18:25:46 GMTNetworkNewsWire: Genprex Inc. (NASDAQ: GNPX) CMO Discusses Recent Company Announcements in Bell2Bell Podcast Episohttps://investorshangout.com/post/view?id=6589149https://investorshangout.com/post/view?id=6589149Fri, 23 Jun 2023 20:19:10 GMTNetworkNewsWire: Genprex Inc. (NASDAQ: GNPX) CMO Video Discusses Advances in Company’s Fight Against Tumors https://investorshangout.com/post/view?id=6587664https://investorshangout.com/post/view?id=6587664Tue, 20 Jun 2023 20:20:04 GMTNetworkNewsWire: NetworkNewsBreaks – Genprex Inc.’s (NASDAQ: GNPX) Flagship Candidate Could Potentially Reshape NShttps://investorshangout.com/post/view?id=6586782https://investorshangout.com/post/view?id=6586782Fri, 16 Jun 2023 21:04:34 GMTNetworkNewsWire: Genprex Inc. (NASDAQ: GNPX) Announces Positive Data From Phase 1 Clinical Trial Evaluating REQORShttps://investorshangout.com/post/view?id=6585872https://investorshangout.com/post/view?id=6585872Wed, 14 Jun 2023 20:55:01 GMTNetworkNewsWire: NetworkNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Eyes Broad-Based Application Potential of ONCOPREhttps://investorshangout.com/post/view?id=6583256https://investorshangout.com/post/view?id=6583256Wed, 07 Jun 2023 20:55:34 GMT